Analytical Validation of a Hybrid Capture–Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA-Reference-Cited by-同舟云学术

Analytical Validation of a Hybrid Capture–Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA

Published:2018-09 Issue:5 Volume:20 Page:686-702
ISSN:1525-1578
Container-title:The Journal of Molecular Diagnostics
language:en
Short-container-title:The Journal of Molecular Diagnostics

Author:

Clark Travis A.,Chung Jon H.,Kennedy Mark,Hughes Jason D.,Chennagiri Niru,Lieber Daniel S.,Fendler Bernard,Young Lauren,Zhao Mandy^ORCID,Coyne Michael,Breese Virginia,Young Geneva,Donahue Amy,Pavlick Dean,Tsiros Alyssa,Brennan Timothy,Zhong Shan,Mughal Tariq,Bailey Mark,He Jie,Roels Steven,Frampton Garrett M.^ORCID,Spoerke Jill M.,Gendreau Steven,Lackner Mark,Schleifman Erica,Peters Eric,Ross Jeffrey S.,Ali Siraj M.,Miller Vincent A.,Gregg Jeffrey P.,Stephens Philip J.,Welsh Allison^ORCID,Otto Geoff A.,Lipson Doron

Publisher

Elsevier BV

Subject

Molecular Medicine,Pathology and Forensic Medicine

Reference46 articles.

1. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing;Frampton;Nat Biotechnol,2013

2. High-throughput genomic profiling of adult solid tumors reveals novel insights into cancer pathogenesis;Hartmaier;Cancer Res,2017

3. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients;Zehir;Nat Med,2017

4. Insurance for broad genomic tests in oncology;Eisenberg;Science,2017

5. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial;Swisher;Lancet Oncol,2017

Cited by 162 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer;Journal of Clinical Oncology;2024-09-05

2. Targeting ALK receptors in non-small cell lung cancer: what is the road ahead?;Expert Opinion on Therapeutic Targets;2024-08-19

3. Identifying key circulating tumor DNA parameters for predicting clinical outcomes in metastatic non-squamous non-small cell lung cancer after first-line chemoimmunotherapy;Nature Communications;2024-08-10

4. Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: the IMMINENT study;Frontiers in Oncology;2024-07-09

5. Use of ctDNA in early breast cancer: analytical validity and clinical potential;npj Breast Cancer;2024-06-19